MedTrace Logo

Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy

NCT00272662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-12-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.

Conditions

  • Chemotherapy Induced Anemia
  • Cancer

Interventions

DRUG

peginesatide

Sponsors & Collaborators

  • Affymax

    lead INDUSTRY

Principal Investigators

  • Affymax · Affymax, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Czechia
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272662 on ClinicalTrials.gov